Clinical toxicology of cannabis and cannabinoids
Programme of the Session
Pharmacology of cannabis and cannabinoids: understanding the basis of toxicity
Department of Medical and Toxicological Critical Care, Lariboisière Hospital Paris-Diderot University INSERM UMRS 1144, Paris, France
Toxicovigilance of synthetic cannabinoids — perspectives from the EU Early Warning System
European Monitoring Centre for Drugs and Drug Addicition (EMCDDA), Lisbon, Portugal
The acute neuropsychiatric effects of cannabis and cannabinoid receptor agonists from a clinical perspective
Emergency Department/Clinical Toxicology Unit, Hospital Universitari Son Espases, Palma de Mallorca, Spain
The complex interaction between cannabinoids and psychiatric and cognitive effects
Department of Psychosis studies, Institute of Psychiatry, Psychology and Neuroscience. King's College London, London, United Kingdom
The cardiovascular effects of cannabis and cannabinoids: myth or reality?
Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust and King's Health Partners, London, United Kingdom
Popularity of cannabis (from a long time) and of the new synthetic cannabinoids (more recently) is attributed to the resulting intense psychoactive effects. These drugs are widely marketed in Europe, easily accessible from the Internet and even with a legal status in some countries . The potency and psychoactive effects of these agents make them hazardous and potentially addictive compounds, leading to cognitive impairments, addiction syndrome and withdrawal symptoms. More recently, increasing evidence has been reported regarding potential cardiovascular toxicity. This symposium will present the pharmacology, epidemiology, acute and chronic toxicity of cannabis and cannabinoids, showing the potential threat resulting from the large consumption of these agents. Molecular mechanisms, newly identified clinical presentations, and debated issues of toxicity will be presented.